Medication Adherence Budgets Rising At Pharma Firms, Report Says, But Impact Still Hard To Calculate
Pharmaceutical companies are investing more money into medication adherence programs, but measuring the success of these programs remains a challenge. Consultants are recommending building adherence plans into the development of a drug, with an emphasis on understanding patients’ approaches to compliance.
You may also be interested in...
A study conducted for the National Community Pharmacists Association assigns chronic medication users report card grades based on rates of different non-adherent behaviors and describes the most common reasons along with some possible remedies.
Drug Development Needs “Clean-Slate Think” To Involve Patients All Along The Way – Pfizer’s Lewis-Hall
Drug companies and other stakeholders should collaborate on developing a “clear framework” for patient engagement, Freda Lewis-Hall says at ISPOR.
In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.